Co-dergocrine (hydergine) in the treatment of tardive dyskinesia.
In a double-blind, placebo-controlled study with co-dergocrine in the treatment of tardive dyskinesia in a group of elderly chronic psychiatric patients the reduction of dyskinetic scores in the group receiving active medication was slightly greater than that in the placebo group; however, this difference did not reach a level of statistical significance. It is suggested that further work could be undertaken with a longer period of treatment, and at a higher dosage level of co-dergocrine, in a younger patient sample.
D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects; D004088:Dihydroergotoxine / Q000627:therapeutic use*; D004311:Double-Blind Method; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011897:Random Allocation
D014150:Antipsychotic Agents; D004088:Dihydroergotoxine